Recurring translocation (10;17) and deletion (14q) in clear cell sarcoma of the kidney

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 3, 2007, Pages 446-451

  Brownlee, Noel A ^a,b,c   Perkins, L Allen ^a   Stewart, Will ^a   Jackle, Beth ^a   Pettenati, Mark J ^a   Koty, Patrick P ^a   Iskandar, Samy S ^a   Garvin, A Julian ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CARCINOGENESIS; CHILD; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 14; CHROMOSOME TRANSLOCATION 10; CLEAR CELL SARCOMA; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY SARCOMA; MALE; PILOT STUDY; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 17; DNA, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KIDNEY NEOPLASMS; MALE; RETROSPECTIVE STUDIES; SARCOMA, CLEAR CELL; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847635763     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Argani P, Perlman EJ, Breslow NE, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol. 2000;24:4-18.
2. Argani P. Clear cell sarcoma. In: Eble JN, Sauter G, Epstein JI, Sesterham IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:56-57. World Health Organization Classification of Tumours; vol 6.
3. Marsden HB, Lawler W. Bone metastasizing renal tumor of childhood: morphological and clinical features, and differences from Wilms' tumor. Cancer. 1978;42:1922-1928.
4. Murphy WM, Grignon DJ, Perlman EJ, eds. Tumors of the Kidney, Bladder, and Related Structures. Washington, DC: Armed Forces Institute of Pathology; 2004:65-75. Atlas of Tumor Pathology; 4th series.
5. Brown KW, Wilmore HP, Watson JE, Mott MG, Berry PJ, Maitland NJ. Low frequency of mutations in the WT1 coding region in Wilms tumor. Genes Chromosomes Cancer. 1993;8:74-79.
6. Zhou J, Fogelgren B, Wang Z, Roe RA, Biegal JA. Isolation of genes from the rhabdoid tumor deletion region in chromosome band 22q11.2. Gene. 2000;241:133-141.
7. DeCristofaro MF, Betz BL, Wang W, Weissman BE. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms tumor. Oncogene. 1999;18:7559-7565.
8. Rubin BP, Chen CJ, Morgan TW, et al. Congential mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congential (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451-1458.
9. Lahoti C, Thorner P, Malkin D, Yeger H. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol. 1996;148:1577-1589.
10. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. Mutations of the p53 tumor suppressor occur infrequently in Wilms' tumor. Cancer Res. 1994;54:2077-2079.
11. Punnett HH, Halligan GE, Zaeri N, Karmazin N. Translocation 10;17 in clear cell sarcoma of the kidney: a first report. Cancer Genet Cytogenet. 1989;41:123-128.
12. Hsueh C, Wang H, Gonzalez-Crussi F, et al. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis. Mod Pathol. 2002;15:606-610.
13. Brownlee NA, Hazen-Martin DJ, Garvin AJ, Re GG. Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma. Pediatr Dev Pathol. 2002;5:257-268.
14. Douglass EC, Wilimas JA, Green AA, Look AT. Abnormalities of chromosomes 1 and 11 in Wilms tumor. Cancer Genet Cytogenet. 1985;14:331-338.
15. Rakheja D, Weinberg AG, Tomlison GE, Partridge K, Schneider NR. Translocation (10;17)(q22;p13): a recurring translocation in clear cell sarcoma of the kidney. Cancer Genet Cytogenet. 2004;154:175-179.
16. Cutcliffe C, Kersey D, Huang CC, Zeng Y, Walterhouse D, Perlman EJ, for the Renal Tumor Committee of the Children's Oncology Group. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res. 2005;11:7986-7994.
17. Wuu W, Soukup S, Bove K, Gotwals B, Lampkin B. Chromosome analysis of 31 Wilms' tumors. Cancer Res. 1990;50:2786-2793.
18. Kaneko, Homma C, Maseki N, Sakurai M, Hata J. Correlation of chromosome abnormalities with histologic and clinical features in Wilms' and other childhood renal tumors. Cancer Res. 1991;51:5937-5942.
19. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbors p53 gene mutations. Nat Genet. 1994;7:91-97.
20. Sreekantaiah C, Davis JR, Sandberg AA. Chromosomal abnormalities in leiomyosarcomas. Am J Pathol. 1993;142:293-305.
21. Kim GJ, Cho SJ, Won NH, et al. Genomic imbalances in Korean hepatocellular carcinoma. Cancer Genet Cytogenet. 2003;142:129-133.
22. Sirchia SM, Sironi E, Grati FR, et al. Losses of heterozygosity in endometrial adenocarcinomas; positive correlation with histopathologic parameters. Cancer Genet Cytogenet. 2000;121:156-162.
23. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002;62:4075-4080.
24. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17:637-641.
25. Megonigal MD, Cheung NK, Rappaport EF, et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A. 2000;97:2814-2819.
26. Orlandi R, Cattaneo M, Troglio F, et al. SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro. Cancer Res. 2002;62:567-574.
27. Cattaneo M, Orlandini S, Beghelli S, et al. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene. 2003;22:6359-6368.
28. Chang JT, Wang HM, Chang KW, et al. Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1. Int J Cancer. 2005;114:942-949.